<SEC-DOCUMENT>0001062993-18-003213.txt : 20180809
<SEC-HEADER>0001062993-18-003213.hdr.sgml : 20180809
<ACCEPTANCE-DATETIME>20180809123507
ACCESSION NUMBER:		0001062993-18-003213
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20180807
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180809
DATE AS OF CHANGE:		20180809

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		181004224

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>August 7,
2018</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="50%" align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="50%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD width="50%" align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code<B><U>(250) 765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>
[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)<BR>
[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
[&nbsp;&nbsp;
]&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))<BR>
</P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=right>Emerging growth company [&nbsp;&nbsp; ]</P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.[&nbsp;&nbsp; ]</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify><B>Item 3.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Unregistered Sales of Equity Securities </B></P>
<P align=justify>On August 7, 2018 Lexaria announced it has issued a total of
355,000 restricted common shares as required by executive consulting agreements,
shared by the Chief Executive Officer and the President of the Company. </P>
<P align=justify>The shares are required to be issued upon certain intellectual
property achievements and patent application filings in March and April
triggered the awards. As a result, 172,500 shares were awarded at an issue price
of US$1.24; and 182,500 shares were awarded at an issue price of US$1.32. Cash
compensation of US$185,200 designed to offset tax liabilities from the share
award was also granted. </P>
<P align=justify><B>Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing that Lexaria has
successfully delivered nicotine in an edible form into blood plasma just minutes
after dosing in an animal <I>in vivo</I> study is filed as exhibit 99.1 to this
current report and is hereby incorporated by reference.</P>
<P align=justify>A copy of the news release announcing that Lexaria has issued a
total of 355,000 restricted common shares as required by executive consulting
agreements is filed as exhibit 99.2 to this current report and is hereby
incorporated by reference. </P>
<P align=justify><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Financial Statements and Exhibits </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD bgColor=#eeeeee >
  <P align=justify><a href="exhibit99-1.htm">Press Release dated August 7, 2018</a></P></TD></TR>
  <TR>
    <TD width="10%">&nbsp;</TD>
    <TD >&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="10%" bgColor=#eeeeee><a href="exhibit99-2.htm">99.2 </a></TD>
    <TD bgColor=#eeeeee >
      <P align=justify><a href="exhibit99-2.htm">Press Release dated August 7,
2018</a></P></TD></TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; August 7,
      2018 </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Bioscience Announces Further Advancement of Edibles
Nicotine Testing </B></P>
<P align=center><B>Delivery Measured Within Minutes </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>&#149; </TD>
    <TD align=left width="95%" >
      <P align=justify><B>Nicotine, in an edible form, delivered to blood plasma
      within minutes after dosing.</B> </P></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="95%" >
      <P align=justify>&nbsp;</P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&#149; </TD>
    <TD align=left width="95%" >
      <P align=justify><B>Statistically significant positive </B><B><I>in vivo
      </I></B><B>results (n=40; two groups of 20 animals).</B> </P></TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="95%" >
      <P align=justify>&nbsp;</P></TD></TR>
  <TR vAlign=top>
    <TD align=left>&#149; </TD>
    <TD align=left width="95%" >
      <P align=justify><B>90.2% greater delivery by the 10-minute mark of the
      study (95% CI; p=0.044) than the</B> <B>study control, and significantly
      greater absorption levels than the control at all subsequent</B> <B>time
      points.</B> </P></TD></TR>
  <TR>
    <TD>&nbsp; </TD>
    <TD width="95%" >&nbsp;    </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left>&#149; </TD>
    <TD align=left width="95%" >
      <P align=justify><B>This study represents Lexaria&#146;s second </B><B><I>in
      vivo </I></B><B>nicotine study, building on the previous</B> <B>nicotine
      breakthrough study announced April 17, 2018.</B> </P></TD></TR></TABLE>
<P align=justify>Kelowna, British Columbia &#150; August 7, 2018 &#150; Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;), a drug delivery
platform innovator, announces that it has successfully delivered nicotine in an
edible form into blood plasma just minutes after dosing in an animal <I>in
vivo</I> study. Lexaria&#146;s DehydraTECH&#153; technology delivered nicotine at each of
the 2, 4, 6, 8 and 10-minute intervals post-dosing, with 90.2% greater delivery
than the concentration-matched control formulation by the 10-minute mark (95%
CI; p=0.044), and significantly greater absorption levels than the control
formulation at all subsequent time points in the study. </P>
<P align=justify>Speed of onset is a key attribute for oral drug administration,
and it is of particular importance for the consideration of non-inhalation
nicotine delivery formats.</P>
<P align=justify>Lexaria contracted a third-party laboratory to perform the
study which focused on detailed analysis of absorption over a 60-minute period,
with particular emphasis on the first 15-minutes after dosing (n=40; two groups
of 20 rats per group; nicotine polacrilex dosage at 10mg/kg). This study is in
follow-up to <I>in vivo</I> study results previously announced on April 17, 2018
which utilized a smaller animal population over a 6-hour period. </P>
<P align=justify>Key highlights are as follows: </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="5%"  >&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="90%" >
      <P align=justify>Peak Level: 79% improvement in peak blood levels (maximum
      concentration or &#147;Cmax&#148;) at 394 ng/mL using Lexaria&#146;s DehydraTECH<SUP>TM
      </SUP>technology vs. 220 ng/mL with the control (95% CI; p=0.0257);
  </P></TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="90%" >
      <P align=justify>Total Quantity: 94% improvement in total quantity of
      nicotine delivered (area under the curve or &#147;AUC&#148;) to the blood during the
      60-minute course of the study, at 266 hr&#149;ng/mL versus 137 hr&#149;ng/mL (95%
      CI; p=0.0086); </P></TD></TR>
  <TR vAlign=top>
    <TD width="5%" >&nbsp;</TD>
    <TD align=left>&#149; </TD>
    <TD align=left width="90%" >
      <P align=justify>Rapidity: Lexaria&#146;s technology delivered nicotine into
      the blood stream by the first time interval of blood sampling at the
      2-minute mark. On average, Lexaria&#146;s technology delivered 203 ng/mL to the
      blood in aggregate of the 2, 4, 6, 8, 10, 12 and 15-minute time points,
      compared to only 120 ng/mL in aggregate over the same period by the
      control, an improvement of 70% (95% CI; p=0.0004).
</P></TD></TR></TABLE>
<P align=justify>A significant amount of data has yet to be received and
analyzed from this study, including brain absorption data. The blood plasma data
from this nicotine study is considered statistically significant and corroborates and confirms the validity of the
results previously announced on April 17, 2018. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left ><BR><BR><BR></TD>
    <TD width="19%" align=center vAlign=bottom nowrap><BR>
      DehydraTECH&#153;
      <BR>Formulation (nicotine <BR>polacrilex 10 mg/Kg) </TD>
    <TD width="19%" align=center vAlign=bottom nowrap>Control <BR>
      Formulation
      <BR>(nicotine polacrilex <BR>10 mg/Kg) </TD>
    <TD width="19%" align=center vAlign=bottom nowrap><BR>
      <BR><BR>% Improvement </TD>
    <TD width="19%" align=center vAlign=bottom nowrap><BR>
    <BR><BR>pValue </TD></TR>
  <TR vAlign=top>
    <TD align=left >Average Nicotine Blood <BR>Level 0-15 min
      (ng/mL) </TD>
    <TD vAlign=bottom align=center width="19%"><BR>203 </TD>
    <TD vAlign=bottom align=center width="19%"><BR>120 </TD>
    <TD vAlign=bottom align=center width="19%"><BR>70 </TD>
    <TD vAlign=bottom align=center width="19%"><BR>0.0004 </TD></TR>
  <TR vAlign=top>
    <TD align=left >Peak Nicotine Blood Level <BR>0-60 min
      (ng/mL) </TD>
    <TD vAlign=bottom align=center width="19%"><BR>394 </TD>
    <TD vAlign=bottom align=center width="19%"><BR>220 </TD>
    <TD vAlign=bottom align=center width="19%"><BR>79 </TD>
    <TD vAlign=bottom align=center width="19%"><BR>0.0257 </TD></TR>
  <TR vAlign=top>
    <TD align=left >Total Nicotine Absorption <BR>(i.e., AUC)
      0-60 min <BR>(hr&#183;ng/mL) </TD>
    <TD vAlign=bottom align=center width="19%"><BR><BR>266 </TD>
    <TD vAlign=bottom align=center width="19%"><BR><BR>137 </TD>
    <TD vAlign=bottom align=center width="19%"><BR><BR>94 </TD>
    <TD vAlign=bottom align=center width="19%"><BR><BR>0.0086
</TD></TR></TABLE></DIV>
<P align=justify>According to the CDC, global deaths from smoking are currently
6 million per year and expected to reach 8 million yearly by 2030. For every
fatality from smoking 30 more people live with serious smoking-related illness.
(www.cdc.gov/tobacco)</P>
<P align=justify>&#147;Lexaria&#146;s DehydraTECH&#153; breakthrough technology is
demonstrating significant effectiveness in delivering nicotine into the
bloodstream much more rapidly than we thought possible, and at levels
approaching two times more effective than controls,&#148; said Chris Bunka, Chief
Executive Officer of Lexaria Bioscience Corp. &#147;If we can develop viable
ingestible alternatives to cigarette smoking we could help hundreds of millions
of people avoid many of the disease states associated with smoking and I cannot
imagine a more rewarding destiny bestowed upon Lexaria Bioscience Corp.&#148; </P>
<P align=justify>Lexaria&#146;s <I>in vitro </I>laboratory, <I>in vivo </I>animal and
human clinical absorption studies have consistently shown faster delivery and
more effective delivery of substances such as nicotine and cannabinoids. Lexaria
continues to focus on advancing both its R&amp;D and commercialization
initiatives with its DehydraTECH<SUP>TM </SUP>technology platform.</P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECH<SUP>TM </SUP>delivery technology. Lexaria&#146;s
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. <BR><U><FONT
color=#0000ff>www.lexariabioscience.com </FONT></U></P>
<P align=justify><img src="tw.jpg" width="49" height="58">For regular updates, connect with Lexaria on Twitter <U><FONT
color=#0000ff>https://twitter.com/lexariacorp </FONT></U><br>
<img src="fb.jpg" width="51" height="54">and on Facebook <U><FONT
color=#0000ff>https://www.facebook.com/lexariabioscience/ </FONT></U></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_3></A>
<P align=center>- 3 - </P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U><FONT color=#0000ff>www.NetworkNewsWire.com
</FONT></U><BR></P>
<P align=justify>FORWARD-LOOKING STATEMENTS <BR>This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that any additional stock warrants or stock options will be
exercised. Such forward-looking statements are estimates reflecting the
Company's best judgment based upon current information and involve a number of
risks and uncertainties, and there can be no assurance that other factors will
not affect the accuracy of such forward-looking statements. Factors which could
cause actual results to differ materially from those estimated by the Company
include, but are not limited to, government regulation, managing and maintaining
growth, the effect of adverse publicity, litigation, competition, the patent
application and approval process and other factors which may be identified from
time to time in the Company's public announcements and filings. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will be able to raise additional capital. There is no assurance that Lexaria
will successfully complete any other contemplated or existing technology license
agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. Scientific R&amp;D is often
unpredictable and unanticipated results could emerge from any study and have a
material impact as can any results that cannot be reproduced in subsequent
testing. There is no assurance that any planned corporate activity, scientific
study, R&amp;D, business venture, or initiative will be pursued, or if pursued,
will be successful. There is no assurance that any of Lexaria&#146;s postulated uses,
benefits, or advantages for the patented and patent-pending technology will in
fact be realized in any manner or in any part. No statement herein has been
evaluated by the Food and Drug Administration (FDA). TurboCBD<SUP>TM</SUP>,
DehydraTECH<SUP>TM </SUP>technology and ViPova<SUP>TM </SUP>products are not
intended to diagnose, treat, cure or prevent any disease. </P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>exhibit99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.2 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Exhibit 99.2 </B></P>
<P align=center><B>Lexaria Awards Share Incentive Related to Recent Patent
Achievements </B></P>
<P align=justify>Kelowna, British Columbia &#150; August 7, 2018 &#150; Lexaria Bioscience
Corp. (OTCQX: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;), a drug delivery
platform innovator, announces that it has issued a total of 355,000 restricted
common shares as required by executive consulting agreements, shared by the
Chief Executive Officer and the President of the Company. </P>
<P align=justify>The shares are required to be issued upon certain intellectual
property achievements and patent application filings in March and April
triggered the awards. As a result, 172,500 shares were awarded at an issue price
of US$1.24; and 182,500 shares were awarded at an issue price of US$1.32. Cash
compensation of US$185,200 designed to offset tax liabilities from the share
award was also granted. </P>
<P align=justify>Lexaria currently has ~49 patents pending or granted around the
world and has fostered an internal environment of intellectual creativity,
incentivizing employees and consultants for successful patent progress. One year
ago, the Company had only ~18 patents pending or granted.</P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECH<SUP>TM </SUP>delivery technology. Lexaria&#146;s
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. <BR><U><FONT
color=#0000ff>www.lexariabioscience.com </FONT></U></P>
<P align=justify><img src="tw.jpg" width="49" height="58">For regular updates, connect with Lexaria on Twitter <U><FONT
color=#0000ff>https://twitter.com/lexariacorp </FONT></U><br>
    <img src="fb.jpg" width="51" height="54">and on Facebook <U><FONT
color=#0000ff>https://www.facebook.com/lexariabioscience/ </FONT></U></P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>
  Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U><FONT color=#0000ff>www.NetworkNewsWire.com
</FONT></U></P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>



<A name="page_2"></A>

<P align="justify">
FORWARD-LOOKING STATEMENTS <BR>
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking
statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking
statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation,
competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs
or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way
support future business activities of any kind. Scientific R&amp;D is often unpredictable and unanticipated results could emerge from any study and have a material impact as can any results that cannot be reproduced in subsequent testing. There is
no assurance that any planned corporate activity, scientific study, R&amp;D, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria&rsquo;s postulated uses, benefits, or
advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). TurboCBD<SUP>TM</SUP>, DehydraTECH<SUP>TM</SUP>
technology and ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or prevent any disease. </P>
<P align="justify">
<I>The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. </I></P>

<HR noshade align="center" width="100%" size=5 color="black">


</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tw.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tw.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  Z #$# 2(  A$! Q$!_\0
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A45HZTVK7,%A:*=^48B! %4  >@IU+161T6L%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>fb.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 fb.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  V #,# 2(  A$! Q$!_\0
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M6!0L3'Y1C%0VY83ILSNSQBM913@0OB/3Z*!THK@L=($9&#7F^J6;66H2P$<
MY4^W:O2*SM8TB'4XOF^650=KBM*4^5D3CS(\]&0>M=AXB!'AR$\\%?Y5S5WI
M=Y9.5E@? Z,!D$4V2ZNYX5BDDD=%Z*><5U37-9IF2=MRKTQ6OX9LC=ZFKD9C
MB^8GUJ+3]#O;YUQ$4CSDNW%=QI]A#I]NL,*\#J>Y-35JI*R'"-]2SR**6BN*
CQN%%%%, (!&",CWJ,6\(;<(8P?4**** )**** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
